During phase-II randomized, double-blind, and placebo-controlled clinical trials, an oral antiviral medication showed positive results against COVID-19 infection.

The antiviral drug Molnupiravir safely and efficiently clear the entire viral load in patients with symptomatic Coronavirus infection when taken in full dose within days.

Molnupiravir was first developed as a preventive medication and therapy for SARS and MERS in the early 2000s by American companies Ridgeback Biotherapeutics LP and Merck & Co. The drug has previously been shown to be effective against a variety of viruses that use an RNA-dependent RNA polymerase, which COVID-19 already has.

Also Read: Jawad Ahmad is not sure of his survival after contracting Covid again

Molnupiravir was given to 202 non-hospitalized adults with confirmed COVID-19 infection and intermittent symptoms for more than a week in phase-II clinical trials.

Five days after acquiring Molnupiravir, 100 percent of the study group’s participants tested negative for Coronavirus, compared to just 24 percent of the placebo group’s participants.

Read more: کورونا وائرس سے 29 فیصد مریضوں کے پھیپھڑے متاثر ہو رہے ہیں، ڈاکٹر جاوید اکرم

Significant outcomes from phase-II clinical trials, according to experts, indicate that Molnupiravir can be a successful medication against Coronavirus. Because of its oral nature, it can also avoid serious symptoms and hospitalization. They say that if an oral-based treatment for COVID-19 had been available a year earlier, many lives might have been saved.